
TMO Stock Forecast & Price Target
TMO Analyst Ratings
Bulls say
Thermo Fisher Scientific is projected to achieve a compound annual growth rate (CAGR) of 5.4% in its lab products and services segment over the next three years, despite a notable decline from the previous growth rate of 16.9% from 2019 to 2024. The company is expected to gain market share in the contract research organization (CRO) sector, driven by an impressive solution set and favorable biopharma clinical trial outsourcing trends, with significant increases anticipated in outsourcing for both early-stage and late-stage drug development. Additionally, revenue from analytical instruments is forecasted to grow at a CAGR of 2.5%, reflecting a more moderate but steady contribution compared to the previous growth rate of 6.2% from 2019 to 2024.
Bears say
Thermo Fisher Scientific has experienced a significant decline in its financial performance from 2021 to 2024, with adjusted EBIT margin decreasing by approximately 830 basis points to 22.6%. Additionally, the firm has faced a steep drop in adjusted gross margin, which fell by around 940 basis points to 42.2%, underperforming relative to the 46.4% gross margin recorded in 2019. This downward trend in profitability metrics raises concerns regarding the company's overall financial health and future growth prospects.
This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.
TMO Analyst Forecast & Price Prediction
Start investing in TMO
Order type
Buy in
Order amount
Est. shares
0 shares